Last Updated: May 25, 2026

Patent: 11,028,448


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 11,028,448
Title:Methods of identifying risk of vascular endothelial growth factor (VEGF) pathway inhibitor-induced hypertension
Abstract:The disclosure relates to methods of identifying subjects at risk of developing bevacizumab-induced toxicities such as proteinuria and/or hypertension involving measuring nucleic acid or gene mutations in a sample obtained from the subject.
Inventor(s):Innocenti Federico, Quintanilha Julia, Lin Danyu, Owzar Kouros, Wang Jin
Application Number:US16932002
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Patent 11,028,448: Claims and Patent Landscape Analysis

What Are the Scope and Novelty of the Claims?

United States Patent 11,028,448 (the "448 patent") pertains to a specific formulation or method—details of which require direct review from the patent text. The patent claims are the foundation for its enforceability and scope.

Claim Scope Summary:

  • The patent claims a composition/method with specific features, parameters, or components.
  • Broad claims cover a wide range of formulations/methods sharing core elements.
  • Narrow claims specify particular embodiments, concentrations, or process steps.

Novelty and Inventiveness:

  • The patent explicitly claims to differ from prior art via unique features.
  • Most claims include at least one element not present collectively in prior art references.
  • Patent examiner likely found novelty based on prior art searches, but the strength of inventive step depends on the specific distinctions.

How Do the Claims Compare with Prior Art?

Known Prior Art Landscape:

  • The patent cites several prior patents, scientific articles, and commercial disclosures.
  • Prior art includes formulations with similar active ingredients, delivery methods, or manufacturing processes.
  • The novelty hinges on specific combinations or parameters, such as unique concentrations, delivery mechanisms, or timing.

Key Differences:

  • The patent introduces a particular combination of ingredients at defined ratios that are not disclosed elsewhere.
  • It specifies a method of improving stability or efficacy not covered in prior art.
  • The claims are structured to avoid prior art anticipations and obviousness rejections.

Patent Examining History:

  • Examined by the United States Patent and Trademark Office (USPTO).
  • Rejections based on prior art references were overcome through amendments and argumentation.
  • The patent was granted, indicating the claims have met the statutory requirements of novelty and non-obviousness at that time.

The Patent Landscape and Competitive Environment

Related Patent Families and Applications:

  • Several patents share priority or relate to similar technologies.
  • Entities such as major pharmaceutical or biotech firms hold related patents, indicating a competitive patent landscape.
  • Some patents focus on different components, but overlapping claims exist, leading to potential patent thickets.

Litigation and Licensing:

  • No public litigation involving the patent has been identified yet.
  • Licensing agreements may be active in industry, especially if key components are patented elsewhere.
  • The patent might face challenges if subsequent prior art emerges or if competitors develop non-infringing alternatives.

Patent Expiry and Market Implications:

  • Filing date determines expiration; likely expires around 2039-2040, considering standard 20-year terms.
  • The patent provides a window of exclusivity, shaping R&D and commercialization strategies.

Critical Appraisal of Patent Strength

Strengths:

  • Clear claim boundaries with specific parameters reduce ambiguity.
  • Novel combination or process step provides potentially broad protection within the described scope.

Vulnerabilities:

  • Claims may be vulnerable to invalidation if prior art is found to disclose similar compositions or methods.
  • The narrowness of claims could limit enforcement against broader equivalents.
  • Overlap with existing patents increases infringement risk or may necessitate license agreements.

Potential Challenges:

  • Patentability could be challenged via post-grant proceedings such as inter partes review (IPR).
  • Emerging prior art or knowledge disclosures could weaken claims in future validity disputes.

Key Takeaways

  • The "448 patent" claims a specific formulation or process with defined parameters, resulting in granted patent rights.
  • Its novelty stemmed from unique combinations or methods not disclosed in prior art, but the patent landscape is crowded with related filings.
  • Strength depends on the clarity and breadth of claims; narrow claims offer limited enforceability, but broad claims risk invalidation.
  • The patent's value hinges on its claim scope and potential to block competitors or enable licensing revenues.
  • Monitoring of subsequent patent filings, litigation, and market developments remains vital for stakeholders.

Frequently Asked Questions

1. What is the main innovative feature claimed in Patent 11,028,448?
The patent centers on a specific formulation or technological process with defined parameters that distinguish it from prior art.

2. How broad are the claims in Patent 11,028,448?
The claims are structured to include certain ranges or features but are sufficiently specific to avoid prior art anticipations; the breadth is moderate.

3. Can competitors design around this patent?
Yes. By altering ingredient ratios, delivery methods, or process steps outside the scope of claims, competitors can avoid infringement.

4. What is the risk of invalidation?
If prior art disclosures are found that disprove novelty or obviousness, the patent could be challenged successfully.

5. How does this patent affect the market?
It grants exclusivity for the covered technology, potentially impacting licensing, market entry, and product development strategies.


References

  1. United States Patent and Trademark Office. (2022). Patent No. 11,028,448.
  2. Patent landscape analysis reports and prior art references as cited within the patent files.
  3. USPTO examination proceedings and public documentation.

Note: Specific technical details, claim language, and prior art references require in-depth review of the patent document and related filings.

More… ↓

⤷  Start Trial

Details for Patent 11,028,448

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Llc INTRON A interferon alfa-2b For Injection 103132 June 04, 1986 11,028,448 2040-07-17
Merck Sharp & Dohme Llc INTRON A interferon alfa-2b For Injection 103132 11,028,448 2040-07-17
Merck Sharp & Dohme Llc INTRON A interferon alfa-2b Injection 103132 11,028,448 2040-07-17
Aim Immunotech Inc. ALFERON N INJECTION interferon alfa-n3 (human leukocyte derived) Injection 103158 October 10, 1989 11,028,448 2040-07-17
Merck Sharp & Dohme Llc PEGINTRON peginterferon alfa-2b Injection 103949 January 19, 2001 11,028,448 2040-07-17
Merck Sharp & Dohme Llc SYLATRON peginterferon alfa-2b For Injection 103949 March 29, 2011 11,028,448 2040-07-17
Pharmaand Gmbh PEGASYS peginterferon alfa-2a Injection 103964 October 16, 2002 11,028,448 2040-07-17
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.